Breakthroughs in RNA editing and radioligand therapies are poised to take biotech into a new era – driving innovation, growth and new investment opportunities Biotechnology is entering a dynamic new ...

After scientists inserted Neanderthal genes into mice, the results left them speechless.

Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...

From the 2010s to the present, the existing technologies in the clinic and operating room have been improved with the goals ...

Speaking at the STAT Summit, Kyle and Nicole Muldoon shared an inside look at how their family went from heartbreak to ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Since 2019, MIT researchers have published a new concept called prime editing, which is more precise than regular CRISPR-Cas9 gene editing. As a result, it has fewer off-target effects and less chance ...

Crispr Therapeutics AG ( ($CRSP) ) has issued an update. On October 15, 2025, CRISPR Therapeutics AG announced the filing of a prospectus ...

The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.

Kansas State University researchers and the state’s farmers are putting their collective support behind a project to reduce ...

The total market capitalization of China’s publicly listed biotech firms has reached $1.5 trillion, second only to that of the United States. As China surges, many traditional American strengths have ...

Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its ...